ArticleMolecular neurobiology2026
In Vitro Analysis of TWEAK/Fn14 Axis in the Blood-Brain Barrier Models during Oxygen-Glucose Deprivation and Reoxygenation.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upregulation of tumor necrosis factor-like weak apoptosis-inducing factor (TWEAK) and its receptor fibroblast growth factor-inducible 14 (Fn14) was observed in stroke patients and murine models, contributing to neuronal apoptosis and blood-brain barrier (BBB) disruption. This study aimed to investigate the TWEAK/Fn14 signaling axis in cerebral ischemia and reperfusion using different in vitro oxygen-glucose deprivation (OGD) durations and cellular models. Western blot and RT-qPCR were used to evaluate TWEAK/Fn14 expression in monocultures, co-cultures, and triple-cultures of human immortalized endothelial cells, pericytes, and astrocytes. Six OGD conditions were tested: 4, 8, and 16 h, with or without 24 h reoxygenation. BBB model integrity was evaluated by analyzing occludin, zonula occludens-1, and VE-cadherin. A significant, duration-dependent downregulation of Fn14 was observed in monocultures after OGD (up to 85%, p < 0.05-p < 0.001), with partial recovery after 24 h reoxygenation (p < 0.05). TWEAK levels remained stable with minor fluctuations. Similar Fn14 reductions were seen in co- and triple-cultures (p < 0.01), followed by recovery. Endothelial biomarkers exhibited an initial stress response post-OGD, followed by recovery during reoxygenation. In conclusion, TWEAK remains stable during ischemia without immune cells, while Fn14 is downregulated during OGD and recovers after reoxygenation, indicating time-dependent roles in ischemic response and repair. The findings indicate a time-dependent regulation of Fn14 under ischemic conditions in vitro, highlighting its role in BBB stress and recovery. Nevertheless, further preclinical studies are needed to establish its therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.